CPVT is predominantly identified in individuals who are carriers of a dominant point mutation in the cardiac ryanodine receptor (RyR2) [7,8,9,10,11]. The gene discussed is RYR2; the disease is catecholaminergic polymorphic ventricular tachycardia.